Advertisement

Document › Details
Adrenomed AG. (8/13/19). "Press Release: Adrenomed AG Takes Part in Four Upcoming Conferences". Hennigsdorf.
![]() |
Organisation | Adrenomed AG |
Organisation 2 | University of Nijmegen (Radboud University) | |
![]() |
Product | adrecizumab |
Product 2 | Sachs Annual Biotech in Europe Forum 2019 Basel | |
![]() |
Person | Hein, Frauke (Deutsche Biotech Innovativ 201211 Managing Director of MLDx GmbH + Adrenomed) |
Person 2 | von Hummel, Julia (MC Services 201811) | |
Adrenomed AG, the vascular integrity company, announced today its participation at four upcoming conferences in Europe. Adrenomed representatives will be available for networking and one-to-one meetings at the following events:
Weimar Sepsis Update – Symposium
September 11th – 13th, 2019, Congress Centrum Neue Weimarhalle, Weimar, Germany
Adrenomed will co-host the lunch symposium “Beyond Standard of Care – New Perspectives on Vascular Integrity in Shock” on September 13th, 12:00 – 13:30 CET.
https://www.sepsis-gesellschaft.de/kongress/
19th Annual Biotech in Europe Forum (Sachs Conference)
September 25th – 26th, 2019, Congress Center Basel, Switzerland
Dr. Frauke Hein, Chief Business Officer of Adrenomed, will participate in the “Platform Technologies & Novel Therapeutics Panel” on September 25th, 10:45 CET.
https://www.sachsforum.com/bef19-about.html
European Business Development Conference (EBDC)
September 25th – 26th, 2019, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany
Dr. Frauke Hein, Chief Business Officer of Adrenomed, will give a “Spotlight Talk on Sepsis” on September 26th, 12:00 CET.
https://www.biodeutschland.org/de/european-business-development-conference-2019.html
32nd European Society of Intensive Care Medicine (ESICM) LIVES
September 28th – October 2nd, 2019, CityCube, Berlin, Germany
Prof. Dr. Peter Pickkers, Radboud University, Department of Intensive Care, Nijmegen, The Netherlands, will give a presentation about “Adrenomedullin in sepsis, effect of the non-inhibitory antibody Adrecizumab”, session “Innovation in sepsis treatment”, on October 1st, 16:20 CET, room Stockholm.
https://www.esicm.org/events/32nd-annual-congress-berlin/
About Adrenomed
Adrenomed AG is a German privately-financed, clinical stage biopharmaceutical company. Adrenomed´s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the Company’s lead product candidate Adrecizumab is a clinical-stage, first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab is currently under clinical evaluation in a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II study with 300 patients suffering septic shock. Excellent safety and tolerability were demonstrated in two Phase I trials. www.adrenomed.com
Adrenomed AG
@adrenomed
Contact
Adrenomed AG
Frauke Hein, Ph.D. (Chief Business Officer)
phone: +49 (0)3302 2077814
fhein@adrenomed.com
Media Inquiries
MC Services AG
Eva Bauer/Julia von Hummel
phone: +49 (0)89 21022880
adrenomed@mc-services.eu
Record changed: 2021-01-05 |
Advertisement

More documents for Adrenomed AG
- [1] Adrenomed AG. (1/4/21). "Press Release: Adrenomed Supervisory Board Appoints Dr. Wolfgang Baiker as CEO". Hennigsdorf....
- [2] Adrenomed AG. (11/30/20). "Press Release: Adrenomed Closes EUR 22 Million Equity Financing to Accelerate Development of Adrecizumab (HAM8101) and Provides Business Update". Hennigsdorf....
- [3] Adrenomed AG. (2/21/20). "Press Release: Adrenomed Announces Positive Top-Line AdrenOSS-2 Phase II Results with Adrecizumab in Septic Shock". Hennigsdorf....
- [4] Adrenomed AG. (9/26/19). "Press Release: Adrenomed Completes Full Enrollment with 300 Patients in AdrenOSS-2 Trial with Adrecizumab in Septic Shock". Hennigsdorf....
- [5] Adrenomed AG. (8/29/19). "Press Release: Adrenomed Supervisory Board Appoints Jens Schneider-Mergener as CEO and Jens Zimmermann, CMO, Joins the Executive Board". Hennigsdorf....
- [6] Adrenomed AG. (5/6/19). "Press Release: Adrenomed AG Takes Part in Three Upcoming Conferences". Hennigsdorf....
- [7] Adrenomed AG. (11/26/18). "Press Release: Adrenomed Closes EUR 24 M Financing Led by Wellington and HBM". Hennigsdorf, Munich & Zug....
- [8] Adrenomed AG. (6/14/18). "Press Release: Adrenomed AG Reveals Adrecizumab Mode of Action". Hennigsdorf....
- [9] Adrenomed AG. (12/11/17). "Press Release: Adrenomed AG Doses First Patient in Proof of Concept Study with Adrecizumab to Treat Patients with Early Septic Shock". Hennigsdorf....
- [10] Deutsche Biotech Innovativ AG. (11/25/15). "Press Release: Deutsche Biotech Innovativ AG Invests Funds from Capital Increase in Clinical Development of Sepsis Drug Adrecizumab". Hennigsdorf....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top